Program areas at The Pituitary Society
In june, 2023, we held our 18th international Pituitary congress in chicago, il. Two hundred and ninety-three attendees from around The world attended The two-and-a-half-day congress. The biennial international Pituitary congress is an educational opportunity for Pituitary specialists, neuroendocrinologists, and neurosurgeons to review The latest research and clinical highlights regarding patients with Pituitary disorders. Specifically, there is a critical need to bring together an international community of laboratory researchers, translational and clinician scientists, and clinicians to consider major advances in Pituitary disorders and tie them to clinical care. This scientific program highlights key advances in understanding basic Pituitary and neuroendocrine regulation and reviews these findings in conjunction with state-of-the-art management of patients with Pituitary tumors, Pituitary deficiency states and neuroendocrine disorders.
The 2022 updates in diagnosis and treatment of patients with acromegaly: personalized approaches and paradigm changes post covid-19 webinar's mission was to update global acromegaly approaches, thereby allowing clinicians worldwide to improve their patients' quality of life, morbidity, and mortality. In order to improve outcomes and quality of life for their patients with acromegaly, healthcare professionals must be made aware of new medical therapy options and treatment strategies in this disease setting.
Over The last decade, most endocrinology fellowship programs reduced The training requirements from 3 years to 2 years to be eligible for board certification. In parallel, diabetes and obesity incidence and prevalence increased significantly, limiting clinical experiences on other rarer, nevertheless severe, and potentially lethal diseases, such as Pituitary disorders. Therefore, The preceptorship course for fellows-in-training, taught by leading international experts, aims to address some of these issues by reviewing for trainees' advancements in diagnosis and treatment of hypopituitarism, growth hormone deficiency, cushing's syndrome, and acromegaly.
The panomen clinical classification workshops seek to establish a comprehensive classification system that guides prognosis and therapy of Pituitary adenomas. The 2022 who histopathology-based classification system can only be applied to certain lesions that are resected, which represent few clinically significant Pituitary adenomas. Through The workshops a new approach is proposed to guide prognosis and therapy of Pituitary adenomas by integrating clinical, genetic, biochemical, radiological, pathological, and molecular information for all adenomas arising from anterior Pituitary cell lineages.changes in The pathological classification of Pituitary adenomas to neuroendocrine tumours has highlighted The need for a comprehensive schema that guides prognosis and outcomes for all Pituitary adenomas, including those that are not surgically excised. We developed a comprehensive classification system for both unresected and resected adenomas, incorporating a wide range of risk factors known to affect morbidity and mortality.